Skip to content

Total debt at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$1.43B+138%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.26B+32,101%
Arrowhead Research logo
Arrowhead ResearchARWR
$107.88M-5.6%
ALN
Alnylam PharmaceuticalsALNY
Biogen logo
BiogenBIIB
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$6.55B+40.3%
Enterprise value$6.11B+77.3%
P/E
P/S7.9×+5.3×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Calculated from PTC Therapeutics’s reported figures.

Plus components not separately reported this period.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTC Therapeutics's total debt?
PTC Therapeutics (PTCT) reported total debt of $395.09M in Q1 2026.
How has PTC Therapeutics's total debt changed year-over-year?
PTC Therapeutics's total debt increased by 0.1% year-over-year, from $394.66M to $395.09M.
What is the long-term trend for PTC Therapeutics's total debt?
Over 5 years (2020 to 2025), PTC Therapeutics's total debt has grown at a -1.1% compound annual growth rate (CAGR), from $421.71M to $398.7M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.